A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima‐media thickness of the carotid artery in hypertensive patients. The Swedish irbesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA)

Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation. Ablation of the OPG gene in mice results in calcification of the aorta and renal arteries. We have previously reported an association between a single nucleotide polymorphism in the promoter region of OPG and vascular morphology and function in healthy humans. The objective with this study was to confirm our previous results in a larger population, and in addition, to study subjects with hypertension. The OPG genotype was determined by restriction fragment length and the intima‐media thickness (IMT) of the common carotid artery was measured by ultrasound in 100 patients with hypertension and left ventricular hypertrophy, and 75 healthy normotensive control subjects. In the hypertensive group subjects with the CC genotype (n = 24) showed a significantly increased IMT compared to those with the TC (n = 52, p = 0.007) and TT (n = 24, p = 0.009) genotype, in the hypertensive group only (mean ± SD for TT = 0.88 ± 0.21 mm, TC = 0.90 ± 0.16 mm, CC = 1.05 ± 0.31 mm). The allele distribution did not differ between hypertensive and control individuals. The present study confirms our previous finding and shows that polymorphism in the promoter region of OPG is associated with vascular morphology in hypertensive subjects.

[1]  L. Hofbauer,et al.  Increased osteoprotegerin serum levels in men with coronary artery disease. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  Y. Ikari,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.

[3]  C. Held,et al.  Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy , 2002, Journal of hypertension.

[4]  H. Melhus,et al.  A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. , 2002, Biochemical and biophysical research communications.

[5]  P. Price,et al.  Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[6]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[7]  S. Cummings,et al.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[8]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[9]  E. Clark,et al.  Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[10]  L. Labree,et al.  Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. , 2000, Atherosclerosis.

[11]  E. Clark,et al.  Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. , 2000, The Journal of biological chemistry.

[12]  J. Mallion,et al.  Relationships between cardiovascular remodelling and the pulse pressure in never treated hypertension , 2000, Journal of Human Hypertension.

[13]  J. Frohlich,et al.  Detection of early atherosclerosis with B mode carotid ultrasonography: assessment of a new quantitative approach. , 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

[14]  L. Lind,et al.  Endothelium-dependent vasodilation and structural and functional changes in the cardiovascular system are dependent on age in healthy subjects. , 1999, Clinical physiology.

[15]  P. Boutouyrie,et al.  Association between local pulse pressure, mean blood pressure, and large-artery remodeling. , 1999, Circulation.

[16]  M A Espeland,et al.  Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. , 1999, Stroke.

[17]  Giuseppe Mancia,et al.  Risk factors associated with alterations in carotid intima—media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis , 1998, Journal of hypertension.

[18]  H. Yasuda,et al.  Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. , 1998, European journal of biochemistry.

[19]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[20]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[21]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[22]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[23]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[24]  P L Allan,et al.  Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. , 1997, Stroke.